<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276159</url>
  </required_header>
  <id_info>
    <org_study_id>05US02IMP-852A</org_study_id>
    <secondary_id>MT2005-20</secondary_id>
    <secondary_id>2005LS057</secondary_id>
    <secondary_id>0509M73467</secondary_id>
    <nct_id>NCT00276159</nct_id>
    <nct_alias>NCT00326937</nct_alias>
  </id_info>
  <brief_title>Study of Immune Response Modifier in the Treatment of Hematologic Malignancies</brief_title>
  <official_title>Phase II Study of 852A Administered Subcutaneously in Patients With Hematologic Malignancies Not Responding to Standard Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat
      certain hematologic malignancies not responding to standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      852A will be administered as a subcutaneous injection (SC) 2 times per week for 12 weeks (24
      doses) with provisions for dose escalation or reduction based on tolerability
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Drug was not available.
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With 852A Response Using Modified Response Evaluation Criteria in Solid Tumors</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Stable disease in Non-Hogkin's Lymphoma = disease that does not satisfy complete (complete regression), partial (&gt; or = 50% reduction) or progressive disease (increase of 25%) by at least a 4-week period. Since Acute Myelogenous Leukemia is not a solid tumor, Complete Response (CR) = &lt;5% blasts with hematopoietic recovery (absolute neutrophil count &gt;500) at 4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Received Steroids</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Number of patients who received steroids allowing successful continuation of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of Immune Activation With Correlative Laboratory Studies</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Concentrations of 852A</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Measurement of peak concentrations of 852A to correlate the side effects of tolerability in patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>852A Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving at least one dose of 852A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>852A</intervention_name>
    <description>Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.</description>
    <arm_group_label>852A Treatment</arm_group_label>
    <other_name>Molecule 852A</other_name>
    <other_name>S-32865</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects are eligible for the study if they meet all of the following

        Inclusion Criteria:

          -  Diagnosis of one of the following hematologic malignancies not responding to at least
             2 standard treatment regimens. Any criteria for persistent or recurrent disease
             acceptable, i.e. ≥5% blasts for acute leukemia.

               -  acute lymphoblastic leukemia (ALL)

               -  acute myeloid leukemia (AML)

               -  non-Hodgkin's lymphoma (NHL)

               -  Hodgkin's lymphoma (HL)

               -  multiple myeloma (MM)

               -  chronic lymphocytic leukemia (CLL)

          -  Performance status - Karnofsky &gt; 50% for patients &gt; 10 years of age or Lansky &gt;50% for
             patients &lt; 10 year of age

          -  Normal organ function within 14 days of study entry

          -  If female and of childbearing potential, are willing to use adequate contraception
             (hormonal, barrier method, abstinence) prior to study entry and for the duration of
             study participation. A female is considered to be of childbearing potential unless she
             has had her uterus removed, had a double oophorectomy, or has been amenorrheic for at
             least 6 months after chemotherapy

        Exclusion Criteria:

          -  Had/have the following prior/concurrent therapy:

               -  Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A
                  (topical or inhaled steroids are allowed)

               -  Investigational drugs/agents within 14 days of first dose of 852A

               -  Immunosuppressive therapy, including cytotoxic agents within 14 days of first
                  dose of 852A (nitrosoureas within 30 days of first dose)

               -  Drugs known to induce QT interval prolongation and/or induce Torsades De Pointes
                  unless best available drug required to treat life-threatening conditions

               -  Radiotherapy within 4 weeks of the first dose of 852A

               -  Hematopoietic cell transplantation 4 weeks of first dose of 852A

          -  Active infection or fever &gt; 38.5°C within 3 days of first dose of 852A

          -  Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by
             medication

          -  History of, or clinical evidence of, a condition which, in the opinion of the
             investigator, could confound the results of the study or put the subject at undue risk

          -  Uncontrolled intercurrent or chronic illness

          -  Active autoimmune disease requiring immunosuppressive therapy within 30 days

          -  Active hepatitis B or C with evidence of ongoing viral replication

          -  Hyperthyroidism

          -  Uncontrolled seizure disorder

          -  Active coagulation disorder not controlled with medication

          -  Pregnant or lactating

          -  Concurrent malignancy (if in remission, at least 5 years disease free) except for
             localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas
             adequately treated

          -  Proven active central nervous system (CNS) disease

          -  Human Immunodeficiency Virus (HIV) positive

          -  Congenital long QT syndrome or abnormal baseline QTc interval (&gt; 450 msec in males and
             &gt; 470 msec in females) after Bazett's correction (QTc msec = QT msec / square root of
             the RR interval in seconds) on screening electrocardiogram (ECG).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Cooley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2006</study_first_submitted>
  <study_first_submitted_qc>January 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <results_first_submitted>March 2, 2010</results_first_submitted>
  <results_first_submitted_qc>April 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2010</results_first_posted>
  <disposition_first_submitted>April 6, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>April 14, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 5, 2010</disposition_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Hematology</keyword>
  <keyword>852A</keyword>
  <keyword>IRM</keyword>
  <keyword>Oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>852A Treatment</title>
          <description>Patients receiving at least 12 doses of 852A.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive all 24 doses of 852A</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>852A Treatment</title>
          <description>Patients receiving at least 12 doses of 852A.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.8" spread="23.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With 852A Response Using Modified Response Evaluation Criteria in Solid Tumors</title>
        <description>Stable disease in Non-Hogkin's Lymphoma = disease that does not satisfy complete (complete regression), partial (&gt; or = 50% reduction) or progressive disease (increase of 25%) by at least a 4-week period. Since Acute Myelogenous Leukemia is not a solid tumor, Complete Response (CR) = &lt;5% blasts with hematopoietic recovery (absolute neutrophil count &gt;500) at 4 weeks.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Includes patients receiving at least 12 doses of 852A study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>852A Treatment</title>
            <description>Patients receiving at least 12 doses of 852A.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With 852A Response Using Modified Response Evaluation Criteria in Solid Tumors</title>
          <description>Stable disease in Non-Hogkin's Lymphoma = disease that does not satisfy complete (complete regression), partial (&gt; or = 50% reduction) or progressive disease (increase of 25%) by at least a 4-week period. Since Acute Myelogenous Leukemia is not a solid tumor, Complete Response (CR) = &lt;5% blasts with hematopoietic recovery (absolute neutrophil count &gt;500) at 4 weeks.</description>
          <population>Includes patients receiving at least 12 doses of 852A study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Received Steroids</title>
        <description>Number of patients who received steroids allowing successful continuation of therapy.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Includes patients receiving at least 12 doses of 852A study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>852A Treatment</title>
            <description>Patients receiving at least 12 doses of 852A.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Received Steroids</title>
          <description>Number of patients who received steroids allowing successful continuation of therapy.</description>
          <population>Includes patients receiving at least 12 doses of 852A study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure of Immune Activation With Correlative Laboratory Studies</title>
        <time_frame>Up to Week 12</time_frame>
        <population>Analysis not done to sale of agent - unable to perform.</population>
        <group_list>
          <group group_id="O1">
            <title>852A Treatment</title>
            <description>Patients receiving at least 12 doses of 852A.</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Immune Activation With Correlative Laboratory Studies</title>
          <population>Analysis not done to sale of agent - unable to perform.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Concentrations of 852A</title>
        <description>Measurement of peak concentrations of 852A to correlate the side effects of tolerability in patients.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Not able to analysis due to sale of agent - unable to perform.</population>
        <group_list>
          <group group_id="O1">
            <title>852A Treatment</title>
            <description>Patients receiving at least 12 doses of 852A.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Concentrations of 852A</title>
          <description>Measurement of peak concentrations of 852A to correlate the side effects of tolerability in patients.</description>
          <population>Not able to analysis due to sale of agent - unable to perform.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 of Treatment through Week 12</time_frame>
      <group_list>
        <group group_id="E1">
          <title>852A Treatment</title>
          <description>Patients receiving at least 12 doses of 852A.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Disease progression NOS</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <description>sweats</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sarah Cooley, MD</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-625-8474</phone>
      <email>cool0023@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

